Aprea Therapeutics (NASDAQ: APRE) 9.9% stake by AIGH Capital

Rhea-AI Filing Summary

AIGH Capital Management LLC, AIGH Investment Partners LLC and Orin Hirschman report their ownership of Aprea Therapeutics, Inc. common stock in an amended Schedule 13G (Amendment No. 3) as of December 31, 2025. The reporting group states beneficial ownership of 651,747 shares of common stock, including 281,206 shares issuable upon exercise of warrants, representing 9.9% of Aprea’s outstanding common stock. They report sole voting power over 370,541 shares and sole dispositive power over the full 651,747 shares. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Aprea Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Aprea Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

03836J102

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 03836J102

1

Names of Reporting Persons

Orin Hirschman

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 370,541.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 651,747.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

651,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 03836J102

1

Names of Reporting Persons

AIGH Capital Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 370,541.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 651,747.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

651,747.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.9 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aprea Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 535 Boylston Street, Boston, MA, 02116
Item 2.
(a)	Name of person filing: This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the "Act"): (i) AIGH Capital Management, LLC, a Maryland limited liability company ("AIGH CM"), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P., and WVP Emerging Manger Onshore Fund, LLC - AIGH Series. (ii) AIGH Investment Partners, L.L.C., a Delaware limited liability company ("AIGH LLC";), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it; (iii) Mr. Orin Hirschman ("Mr. Hirschman"), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock (as defined in Item 2(d) below) indirectly held through AIGH CM, directly by AIGH LLC and Mr. Hirschman and his family directly. AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the "Reporting Persons." Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
(b)	Address or principal business office or, if none, residence: The principal office and business address of AIGH Capital Management LLC, AIGH Investment Partners LLC, and Mr.Hirschman is: 6006 Berkeley Avenue, Baltimore MD 21209
(c)	Citizenship: See Item 2(a) above and Item 4 of each cover page.
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 03836J102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 651,747 Includes 281,206 common shares issuable upon exercise of warrants
(b)	Percent of class: 9.9 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 370,541
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 651,747 Includes 281,206 common shares issuable upon exercise of warrants
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Orin Hirschman

Signature:	/s/ Orin Hirschman
Name/Title:	Orin Hirschman
Date:	01/28/2026

AIGH Capital Management LLC

Signature:	/s/ Orin Hirschman
Name/Title:	Orin Hirschman, Managing Member
Date:	01/28/2026

FAQ

What ownership stake in Aprea Therapeutics (APRE) is reported in this Schedule 13G/A?

The filing reports beneficial ownership of 651,747 Aprea Therapeutics common shares, representing 9.9% of the class. This total includes both currently held shares and additional shares issuable upon exercise of warrants held by the reporting group.

Who are the reporting persons in the Aprea Therapeutics (APRE) Schedule 13G/A Amendment No. 3?

The reporting persons are AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman. Hirschman is Managing Member of AIGH Capital Management and president of AIGH Investment Partners, and they jointly report their beneficial ownership of Aprea common stock.

How many Aprea Therapeutics (APRE) shares are tied to warrants in this 13G/A filing?

The filing states that 651,747 shares are beneficially owned, which includes 281,206 Aprea common shares issuable upon exercise of warrants. These warrant-linked shares are part of the total reported beneficial ownership and factor into the 9.9% ownership percentage.

What voting and dispositive power is reported over Aprea Therapeutics (APRE) shares?

The reporting persons indicate sole voting power over 370,541 Aprea common shares and sole dispositive power over 651,747 shares. They report no shared voting or shared dispositive power, clarifying how control over these securities is allocated within the group.

Is the Aprea Therapeutics (APRE) stake reported as a control-seeking position?

The stake is described as acquired and held in the ordinary course of business, not to change or influence control of Aprea. The certification explicitly states the securities are not held in connection with any transaction aimed at influencing control, aside from limited nomination activities.

What event date triggers this Aprea Therapeutics (APRE) Schedule 13G/A Amendment No. 3?

The relevant event date for the amended Schedule 13G is December 31, 2025. Holdings as of that date are used to calculate the 651,747 beneficially owned shares and the 9.9% ownership percentage disclosed by the reporting persons.